NCT03457948: Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases |
|
|
| Active, not recruiting | 2 | 32 | US | Arterial Embolization, TAE, Transarterial Embolization, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, 177Lu-DOTATATE, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization, Yttrium-90 Microsphere RE | Nicholas Fidelman, MD, Merck Sharp & Dohme LLC, BTG International Inc. | Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm | 05/24 | 05/26 | | |
